JACKSONVILLE, Fla. — The parents of four-year-old Harlow Higbee say they fear a treatment that has dramatically improved their daughter’s quality of life could soon be cut off for her and other ...
Opinion
12dOpinion
Hope for PDCD Foundation Delivers Petition to FDA Urging Approval of the First Targeted PDCD Treatment
The FDA declined to approve a targeted treatment for PDCD – sodium dichloroacetate (DCA) – in September 2025 despite encouraging clinical evidence and the voices of PDCD families reinforcing the ...
DCA was well-tolerated, even upon chronic administration for over three years. The most commonly reported adverse reaction occurring in >5% of patients was gastrointestinal disorders (n=2, 5.9%). The ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback